Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 155

Results For "import"

2005 News Found

SPAG appoints Ritika Jauhari as President- Strategy & New Business
People | March 14, 2022

SPAG appoints Ritika Jauhari as President- Strategy & New Business

Ritika has also extensively worked with clients such as WHO, GAVI Alliance, USAID, Gilead, Novartis, Sanofi Pasteur


Applications for PLI in bulk drugs extended till March 31st 2022
News | March 14, 2022

Applications for PLI in bulk drugs extended till March 31st 2022

A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore


Dr Federica Fiorini is the winner of the 2022 Darlene Solomon award
News | March 14, 2022

Dr Federica Fiorini is the winner of the 2022 Darlene Solomon award

The award recognizes and supports promising women scientists


Indian pharma companies must become the global benchmark of quality: Amit Jaju, Sr. MD, India, Ankura Consulting
interviews | March 13, 2022

Indian pharma companies must become the global benchmark of quality: Amit Jaju, Sr. MD, India, Ankura Consulting

Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements


S.M.A.R.T. Radianz Vascular Stent System approved for transradial use in the U.S.
Medical Device | March 13, 2022

S.M.A.R.T. Radianz Vascular Stent System approved for transradial use in the U.S.

It signals Cordis' renewed investment in innovation


New data show Lynparza demonstrated overall survival benefit in early breast cancer
Biotech | March 12, 2022

New data show Lynparza demonstrated overall survival benefit in early breast cancer

Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial


Terran Biosciences acquires Concert’s CNS therapeutics portfolio
News | March 12, 2022

Terran Biosciences acquires Concert’s CNS therapeutics portfolio

These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed


China approves BeiGene’s tislelizumab
Drug Approval | March 12, 2022

China approves BeiGene’s tislelizumab

Tislelizumab is now approved for seven indications in China


AbbVie’s Phase 3 data of Atogepant indicates positive outcome for migraine treatment
Biotech | March 11, 2022

AbbVie’s Phase 3 data of Atogepant indicates positive outcome for migraine treatment

Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally


Glaucoma is the leading cause of irreversible blindness in India: Mr. Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals
interviews | March 10, 2022

Glaucoma is the leading cause of irreversible blindness in India: Mr. Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals

As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma